Osprey Pharmaceuticals USA
San Francisco
About Osprey Pharmaceuticals USA
Osprey Pharmaceuticals USA is a clinical stage company focused on the development of novel protein therapeutics for the treatment of inflammatory and immune diseases. The company is advancing a pipeline of proprietary fusion protein therapeutics known as Leukocyte Population Modulators (LPMs) that are designed to selectively target and neutralize chemokine-activated leukocytes underlying a variety of inflammatory and immune diseases. The Company’s lead candidate, CCL2-LPM targeting the CCR2 chemokine receptor expressed by certain pathologically activated leukocytes is in a Phase Ib clinical trial for the treatment of IgA nephropathy.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $29.7M
- Funding stage: Early Stage Venture
- Last round: Series A (May 2009)
- Website: ospreypharma.com
- Phone: 415-352-6262
Industries & Categories
Biotechnology, Medical, Pharmaceutical
Canonical: https://fsome.com/organization/osprey-pharmaceuticals-usa-3287019 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.